N/A N=238 Very-Low Nicotine Cigarettes and Non-Daily Smokers
Smoking
Primary: Change in Cigarette Consumption — -1.6; -0.05 cigarettes per day — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=984 Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
Smoking
Primary: Levels of High Density Lipoprotein C (HDL-C). — 54.1; 50.9; 56.3; 52.8 mg/dL — p=<0.001
N/A N=3,125 Nonsmokers Helping Smokers Quit
Smoking Cessation
Primary: Number of Participants Reporting 30-day Abstinence — 203; 222; 135 Participants
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
N/A N=33 Impact of Switching to Non-Menthol Cigarettes Among Smokers
Tobacco Use
Primary: Total Number of Cigarettes Smoked — 2.2 cigarettes per day
N/A N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=450 E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease
Tobacco Use · E-Cigarette Use · Cardiovascular Diseases
Primary: Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge — 4.25; 4.89; 5.31 Percent change from resting diameter — p=.494
Early Phase 1 N=34 Nicotine Reinforcement and Aversion in Young Adult Light Smokers
Nicotine Addiction
Primary: DEQ - Pleasurable — 2.14; 2.05; 1.98; 2.37 score on a scale
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
N/A N=68 Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
Nicotine · Vaping · Nicotine Vaping
Primary: 3-HPMA — 657.46; 726.84; 703.29; 724.06 ng/mg creatinine
N/A N=149 Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches
Tobacco Use
Primary: NNAL Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days — 363; 274; 312; 293 ng/g — p=<.0001
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=974 Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
Inflammation · Oxidative Stress · Smoking
Primary: Carboxyhemoglobin (COHb) in Blood — 3.07; 1.52; 1.49 % of CO saturated hemoglobin — p=<0.001
N/A N=60 Smoking Topography and Harm Exposure in Menthol Cigarettes
Cigarette Smoking Toxicity
Primary: Smoking Topography- Puff Volume — 518; 661; 650; 620 mL
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
N/A N=67 Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
N/A N=30 Switching to Potential Reduced Exposure Products in Adult Smokers
Tobacco Use Disorder · Oral Nicotine Pouch Use · Smoking Behaviors
Primary: Number of Cigarettes Smoked Per Day (Log-transformed) — 2.0; 1.8 number of cigarettes smoked
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Phase 2 N=234 Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid
Smoking Cessation
Primary: Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes — 14; 14; 32; 36 Participants
N/A N=60 Pharmacokinetic and Subjective Effects of Heated Tobacco Products
Tobacco Use
Primary: Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment — 6.426; 7.953; 8.288; 7.993 ng/mL
Phase 3 N=31 Project Q Pilot: Smoking Cessation for Light Smokers
Tobacco Use Cessation
Primary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants
N/A N=401 Real-Life Passive Exposure Assessment of IQOS
Environmental Exposure
Primary: NEQ: (Non-Exposure Event) — 0.03845; 4.159; 5.695; 0.06876 mg/g
N/A N=15 Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Electronic Cigarette Use · Smoking, Cigarette · Nicotine Dependence
Primary: Study Feasibility — 15 Participants
N/A N=104 Does Switching to Nicotine Containing Electronic Cigarettes Reduce Health Risk Markers
Tobacco Dependence
Primary: Urinary NNAL Concentration — 151.6; 338.2 ng/ml — p=0.0039
N/A N=225 The Get Quit - Stay Quit Study
Nicotine Dependent Cigarette Smoker
Primary: Number of Participants Reporting no Tobacco Use in the Past 7 Days and Have a Validated CO <10ppm — 61; 55 Participants — p=.65